← All organizations
Highest phase reached
Phase 3
First clinical trial
May 19, 2018Last known activity
Oct 1, 2024
Timeline
No events for the selected filters.
Drugs by trial phase (20 distinct, 16 trials)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (9 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
Recent trials (17)
- NCT06539091OfficialPhase 3Oct 1, 2024
- NCT06480630OfficialPhase 2Jul 1, 2024
- NCT06415500OfficialPhase 1May 6, 2024
- NCT06362967OfficialPhase 2May 1, 2024
- NCT06462508OfficialEarly Phase 1Apr 20, 2024
- NCT06462495OfficialEarly Phase 1Apr 10, 2024
- NCT06333821OfficialPhase 3Apr 1, 2024
- NCT06569108OfficialPhase 3Apr 1, 2024
- NCT06312475OfficialPhase 3Jan 9, 2024
- NCT06092047Overall official - principal investigatorEarly Phase 1Oct 31, 2023
- NCT05955677Study chairEarly Phase 1Jul 10, 2023
- NCT05421429Overall official - principal investigatorPhase 2Jul 7, 2022
- NCT05044169Lead sponsorN/ASep 30, 2021
- NCT04601181Overall official - principal investigatorPhase 1Oct 23, 2020
- NCT04601181CollaboratorPhase 1Oct 23, 2020
Details
- Last known activity
- Oct 1, 2024